Ignite Creation Date:
2025-12-25 @ 5:11 AM
Ignite Modification Date:
2026-02-27 @ 3:14 AM
Study NCT ID:
NCT02541227
Status:
TERMINATED
Last Update Posted:
2022-04-06
First Post:
2015-08-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cerebrolysin REGistry Study in Stroke
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000083242', 'term': 'Ischemic Stroke'}], 'ancestors': [{'id': 'D020521', 'term': 'Stroke'}, {'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C006952', 'term': 'cerebrolysin'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1823}, 'targetDuration': '90 Days', 'patientRegistry': True}, 'statusModule': {'whyStopped': 'The goal to match 1000 patients per group could not be achieved with reasonable effort and in reasonable time.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2014-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-03', 'completionDateStruct': {'date': '2021-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-03-28', 'studyFirstSubmitDate': '2015-08-28', 'studyFirstSubmitQcDate': '2015-09-03', 'lastUpdatePostDateStruct': {'date': '2022-04-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2015-09-04', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Modified Rankin Scale', 'timeFrame': '90 days', 'description': 'Ordinal analysis of the mRS on day 90 was chosen as statistically powerful primary endpoint, as it is robust to case mix, clinically relevant and treatment-responsive.'}], 'secondaryOutcomes': [{'measure': 'The National Institutes of Health Stroke Scale (NIHSS)', 'timeFrame': '90 days', 'description': "Ordinal NIHSS at 3 months after stroke onset\n\no Home Time (number of nights among the first 90 days after stroke onset that the patient spends in his own or a relative's private home)"}, {'measure': 'Montreal Cognitive Assessment (MoCA)', 'timeFrame': '90 days', 'description': 'Ordinal MoCA assessment of cognitive functions at 3 months after stroke'}, {'measure': "Home Time (number of nights among the first 90 days after stroke onset that the patient spends in his own or a relative's private home)", 'timeFrame': '90 days'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Ischemic Stroke']}, 'descriptionModule': {'briefSummary': 'Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.', 'detailedDescription': "Stroke is a devastating disease and one of the primary causes for death and long term morbidity imposing a heavy burden on patients, relatives and the health care system. Except for fibrinolytic therapy, which is only possible in a minor fraction of patients, there is no widely approved medication for the treatment of acute stroke.\n\nCerebrolysin has been approved for the treatment of stroke in over 45 countries worldwide.\n\nSince the approval of Cerebrolysin, stroke therapy has evolved, namely, with improved overall care, stroke units, more targeted rehabilitation, and the increasing availability of fibrinolytic therapy (rtPA, Actilyse) in specialized centers throughout the world. More recently, interventional therapies with various thrombus retrievers have emerged.\n\nIn addition the Cerebrolysin treatment in stroke has evolved with different time windows, dosages and lengths of therapy being given in a pragmatic way by physicians within the specification of Product Characteristics for Cerebrolysin (SPC). The main aim of this study is to capture these variables of the Cerebrolysin treatment and its comedication in order to give guidance to further research. This research may consist of an extension of the current registry or targeted research in one or several subgroups of patients responding to Cerebrolysin treatment.\n\nIt is therefore the overall aim of this registry study to monitor the effectiveness and safety of Cerebrolysin therapy against the background of the now established and evolving stroke therapies. In the concomitant control group these therapies alone or in combination will be compared to the addition of Cerebrolysin in these patients. Of particular interest is the treatment in stroke units, with rtPA and systematic rehabilitation.\n\nAn open observational treatment design has been chosen to collect data to capture the therapies as applied in real clinical practice and to avoid the selection bias typical for controlled studies excluding the majority of patients from participation. In order to overcome the observational bias as major and inherent limitation of open trial designs, a remote and blinded assessment will be done: after three months treatment the patients' assessment of the modified Rankin Scale (mRS, a widely accepted primary outcome parameter) will be -after specific informed consent- video-taped and subsequently assessed by at least two independent and blinded assessors experienced in the remote assessment of the mRS."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'All patients receive acute ishemic stroke care according to local treatment standards, not amended or influenced by the study', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Signed informed consent\n* Clinical diagnosis of acute ischemic stroke\n* Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)\n* Reasonable expectation of successful follow-up (max. 100 days)\n\nExclusion Criteria:\n\n* none"}, 'identificationModule': {'nctId': 'NCT02541227', 'acronym': 'CREGS-S', 'briefTitle': 'Cerebrolysin REGistry Study in Stroke', 'organization': {'class': 'INDUSTRY', 'fullName': 'Ever Neuro Pharma GmbH'}, 'officialTitle': 'Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke', 'orgStudyIdInfo': {'id': 'EVER-GB-0514'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cerebrolysin group', 'description': 'Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization', 'interventionNames': ['Drug: Cerebrolysin']}, {'label': 'Control group', 'description': 'Patients who are not treated with Cerebrolysin; treatment follows local clinical practice'}], 'interventions': [{'name': 'Cerebrolysin', 'type': 'DRUG', 'description': 'Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization', 'armGroupLabels': ['Cerebrolysin group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '4024', 'city': 'Linz', 'country': 'Austria', 'facility': 'AKH Linz', 'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}], 'overallOfficials': [{'name': 'Kennedy Lees, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'University of Glasgow'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ever Neuro Pharma GmbH', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'SITS International', 'class': 'NETWORK'}], 'responsibleParty': {'type': 'SPONSOR'}}}}